Vera Therapeutics, Inc. 4

Fordyce Marshall, President and CEO of Vera Therapeutics, exercised 18,500 options and sold 18,500 shares of Class A Common Stock on June 23, 2026 under a Rule 10b5-1 plan.

On June 23, 2026, Vera Therapeutics President and CEO Fordyce Marshall exercised 18,500 stock options at an exercise price of $2.8968 per share, acquiring 18,500 shares of Class A Common Stock, and then sold the same 18,500 shares in market transactions under a pre-arranged Rule 10b5-1 trading plan. The sales occurred in two line items: 18,412 shares at a weighted-average price of $37.9311 per share and 88 shares at $38.43 per share, implying total sale proceeds of roughly $701,000 and an exercise cost of about $53,600, for a net spread of approximately $647,000. Following these transactions and the correction noted in this amended Form 4, Marshall beneficially owned 253,744 shares of Vera Therapeutics’ Class A Common Stock directly, representing an estimated holding value of about $9.6 million based on the reported sale prices.

Filing Facts

CIK

1831828

Ticker

VERA

Form

4

Source Type

fda

Accession

0001859453-26-000012

Alert Tier

6